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Abstract
The most common method for detection of drug resistant (DR) TB in resource-limited settings (RLSs) is indirect
susceptibility testing on Lowenstein-Jensen medium (LJ) which is very time consuming with results available only after 2–
3 months. Effective therapy of DR TB is therefore markedly delayed and patients can transmit resistant strains. Rapid and
accurate tests suitable for RLSs in the diagnosis of DR TB are thus highly needed. In this study we compared two direct
techniques - Nitrate Reductase Assay (NRA) and Microscopic Observation Drug Susceptibility (MODS) for rapid detection
of MDR-TB in a high burden RLS. The sensitivity, specificity, and proportion of interpretable results were studied. Smear
positive sputum was collected from 245 consecutive re-treatment TB patients attending a TB clinic in Kampala, Uganda.
Samples were processed at the national reference laboratory and tested for susceptibility to rifampicin and isoniazid with
direct NRA, direct MODS and the indirect LJ proportion method as reference. A total of 229 specimens were confirmed as
M. tuberculosis, of these interpretable results were obtained in 217 (95%) with either the NRA or MODS. Sensitivity,
specificity and kappa agreement for MDR-TB diagnosis was 97%, 98% and 0.93 with the NRA; and 87%, 95% and 0.78 with
the MODS, respectively. The median time to results was 10, 7 and 64 days with NRA, MODS and the reference technique,
respectively. The cost of laboratory supplies per sample was low, around 5 USD, for the rapid tests. The direct NRA and
MODS offered rapid detection of resistance almost eight weeks earlier than with the reference method. In the study
settings, the direct NRA was highly sensitive and specific. We consider it to have a strong potential for timely detection of
MDR-TB in RLS.
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Introduction
Tuberculosis (TB) continues to be a leading public health
problem in the developing countries, with Sub Saharan Africa
being hardest hit [1]. Besides HIV/AIDS, drug-resistance is now
recognized as one of the major factors underlying the failure to
control TB [2]. Drug resistance in M. tuberculosis (MTB) develops
by sequential selection following exposure to TB drugs [3]. In most
of the low income Sub-Saharan African countries, only first line
drugs [isoniazid (INH) and rifampicin (RIF), Ethambutol (ETH)
and Pyrazinamide (PZA)] are available for TB treatment. Thus,
multi drug resistance (MDR) - defined as resistance to at least INH
and RIF is currently the main concern. The prevalence of MDR-
TB in Africa remains largely unknown but is estimated to be
between 1–4% among new and 4–17% among re-treatment TB
cases [4]. The high number of TB cases per year in each of the
high burden African countries [1] by itself implies that even a
limited prevalence of MDR-TB represents a significant pool of
potentially infectious MDR-TB cases. Timely detection of these
cases is crucial for patient management and control of further
MDR transmission [5].
Indirect susceptibility testing on Lowenstein-Jensen (LJ) medium
is the most common method for detection of TB drug resistance in
Africa. With this method, results take 2–3 months and during this
period patients are given inappropriate drug regimens with poor
responses and they continue to spread MDR strains, which might
be causing MDR-TB outbreaks [6]. Commercial liquid culture
techniques, such as the Mycobacterium Growth Indicator Tube
(MGIT 960: Becton Dickinson, Sparks, Maryland) and line probe
assays [7–8] allow more rapid detection of resistance, and have
been recommended by the WHO [9–10]. However, the
investment and recurrent costs is an obstacle for the broad
implementation of these techniques in the resource-limited settings
(RLSs) of Africa. Therefore, the need for a rapid, affordable,
accurate and easy to use test for MDR-TB in RLSs remains a
priority.
The Nitrate Reductase Assay (NRA) and the Microscopic
Observation Drug Susceptibility (MODS) are two of the most
promising rapid tests for MDR-TB proposed for RLSs. Both
techniques have been reported to be low cost in-house assays that
can be applied directly on smear positive sputum [11]. Resistance
detection with the NRA is based on visual observation of a pink to
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reagent, due to nitro-reductase enzymes in metabolically active
mycobacterial cells converting nitrate to nitrite [12]. MODS relies
on microscopic observation of characteristic cord-like structures in
the drug-containing wells of a tissue culture plate where resistant
MTB cells are growing [13].
In 2009, we conducted a meta-analysis of studies of the direct
NRA and MODS, and the pooled data showed high sensitivity
and specificity for detection of resistance to RIF and INH [11].
The direct NRA has been studied in Brazil, India and Nigeria with
good results [14–16], but these studies had limitations. For
example in the Brazil study, the direct proportion method was the
reference test, while in Nigeria only 20 sputum samples were
studied. The World Health Organization (WHO) in July 2010
recommended the use of NRA and MODS to screen for MDR-TB
in RLSs, but the available data to support the direct NRA was
admittedly limited [17]. It is of priority to obtain sufficient data on
these tests before full scale recommendation of their implemen-
tation in Africa.
In this study we provide more recent data and field experience
with the NRA and MODS assays in the East African country of
Uganda, a typical RLS. The assays were prospectively compared
side by side for interpretable susceptibility results, contamination
rates, sensitivity and specificity, time to results and cost per sample
on a consecutive population of previously treated TB patients
attending a TB clinic in Kampala. The study was approved by the
Research and Ethics Committee of Makerere University College
of Health Sciences Kampala, Uganda.
Methods
Study settings
The study was conducted at Mulago National Referral Hospital
and at the National Reference Laboratory (NRL), Kampala
Uganda. Mulago is a 1500-bed tertiary hospital belonging to the
ministry of health, Uganda. With its free medical care, the hospital
is particularly attractive for the peri-urban low income population
around the capital Kampala where the TB incidence is highest.
The hospital has a TB treatment centre where most TB suspects
and microscopy-confirmed patients are referred for care. Around
4 500 patients are treated at the centre annually, 15–20% of
whom are estimated to be re-treatment cases (Mulago Hospital TB
register, 2006). About one kilometer away from Mulago is the
NRL, which is a P2 TB laboratory facility belonging to the
National TB Control Program (NTP). At the beginning of this
study, the LJPM was the only assay for DST used at the NRL. The
laboratory successfully participates in external quality assurance
under the WHO supranational reference (SNRL) network.
Study patients
Previously treated (re-treatment) TB suspects - return-after-
default, treatment failures and relapses [3] were studied. Only
those who were positive at Ziehl-Neelsen (ZN) smear microscopy
were recruited into the study. A sample size of 250 smear positive
patients was calculated using a simple nomogram - a statistical tool
for calculation of sample size in diagnostic studies [18]. This
calculation was based on a minimum required sensitivity of 95%
for a direct MDR-TB test, 95% confidence interval of +/27 and
based on an estimated prevalence of MDR-TB of 15% among the
re-treatment TB cases at Mulago hospital.
Patient screening and recruitment
Over an 18-months period beginning February 2008, routine
ZN smear microscopy was done on at least two sputum
specimens from all 697 re-treatment TB suspects reporting at
the TB clinic (see figure 1). Of these, 267 (38%) were positive for
acid fast bacilli, and they were requested to consent to the study
irrespective of the smear grade [19]. Of these, 254 (95%) gave
written consent to join the study. Two or three spot sputum
specimens were then collected from each of these patients in
50 ml polypropylene tubes, before initiation of the WHO
standard category II drug regimen [20]. Samples were packaged
according to packing instruction 650 for Category B specimens
[21] and transported at room temperature to the NRL. In case of
delays of more than 2 hours, samples were kept at the clinic at 4–
8uC until transported.
Specimen processing and inoculum preparation
Specimens were processed immediately at the NRL, but a few
specimens were kept at 4–8uC within the NRL for one or two days
if brought in late on Friday evening. Each of the specimens was
processed individually with the N-acetyl-L-cysteine–NAOH–sodi-
um citrate method with NAOH at final concentration of 1.5%
instead of the conventional 4% [22]. It is now routine practice at
the NRL to process sputum with 1.5% NAOH final concentration
to minimize the rampant culture contamination. The sediment in
each tube was reconstituted with phosphate buffered saline (PBS)
to 2.5 ml, mixed well and then pooled into one tube that served as
common inoculum source for all subsequent tests.
Direct nitrate reductase assay (NRA)
The LJ-NRA medium was prepared in-house. Mineral salts,
homogenized egg solutions and malachite green were mixed as in
the preparation of LJ medium. Potassium nitrate was added at a
concentration of 1000 mg/ml. INH and RIF (SigmaH) stocks were
prepared as previously described [23], and were included in the
medium at 0.2 mg/ml and 40 mg/ml, respectively. To keep the test
less laborious, before inoculations, no further sample dilutions
were made. Instead, three-hundred microlitres of the sediment was
inoculated on each of three drug-free controls (day 10, 14 and 21),
and on the INH and RIF- tubes and incubated at 37uC. On the
10
th day, 200 ml of Griess reagent (a solution of hydrochloric acid
50% (vol/vol), sulfanilamide 0.2% wt/vol, and N-(1-naphtyl)ethy-
lene-diamine dihydrochloride 0.1% (wt/vol) mixed in ratio of 1: 2:
2) was added to one control tube in class II bio safety cabinet
(BSC) in a bio safety level 2 facility. If a pink to purple color
developed, the reagent was also added to the two drug containing
tubes. A pink-purple color in the drug tube indicated resistance. If
none or only a faint pink color developed in the control tube, the
slopes were re-incubated until the 14
th or 21
st day when Griess
reagent was added to the second or third control tube,
respectively, and then to the drug tubes.
MODS assay
This assay was performed in a 24-well plate. Each well
contained 700 ml of Middlebrooke 7H9 broth, 100 ml of a cocktail
of polymyxin B, Amphotericin B, Nalidixic acid, trimethoprim and
azlocillin (PANTA: BDH), 100 mL of solutions of INH 1 mg/ml or
RIF 10 mg/ml and 100 ml of the processed specimen, giving a final
volume of 1 ml/well, and critical concentrations of 0.1 mg/ml
INH and 1 mg/ml RIF. A sterility control well with 7H9 broth-
PANTA, and a growth control well with these plus the inoculum
was included for each sample. Plates were sealed with tape and
ziplock bags and incubated at 37uC. Plates were examined under
an inverted microscope at620 and640 for cord-like structures on
days 7, 10, 14 and 21. Daily readings were not practical in the
study settings with few laboratory staff. For interpretability of
results, the positive control well had to show cordlike structures
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resistant if cord-like structures were observed both in drug-free and
drug-containing wells, and susceptible if cords were seen only in
the drug-free controls.
Indirect LJPM
The reference test was performed and interpreted according to
standard procedures with the recommended critical concentra-
tions of 0.2 mg/ml INH and 40 mg/ml RIF [24].
Speciation and testing for discrepant results
All samples in this report were also tested with the GenotypeH
MTBDRplus assay (Hain Lifescience GmbH, Germany) to
confirm the presence of MTB complex band [7]. Results of the
GenotypeH MTBDRplus test were also used to cross-check
discordant results. This test detects mutations in the 81-bp hot
spot region of the rpob gene for RIF resistance and in the katG gene
or inhA promoter region for INH resistance [7].
Repeat testing
A portion of the inoculum was frozen at minus 20uC, to be used
if initial direct DST with the NRA, MODS or GenotypeH
MTBDRplus assay were un-interpretable.
Time to results (TTR)
The dates of DST inoculation and reading of interpretable
results for each sample were recorded and the days to results were
calculated for the NRA, MODS and LJPM assays. Interpretable
results referred to either ‘resistant’ or ‘susceptible’. Un-interpret-
able results referred to results such as ‘no growth’ or ‘contaminated
tube/well’ where no result could be obtained even after repeat
testing.
Cost estimation of the direct NRA, MODS and LJPM
An estimation of the costs of laboratory supplies and
consumables were performed based on prices given by a local
supplier and Fisher ScientificH UK catalog 2009–2010. We added
Figure 1. Patient screening, recruitment and laboratory assays.
doi:10.1371/journal.pone.0019565.g001
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other indirect costs were not assessed.
Data analysis
Nine samples were used for piloting the processes/methods,
thus final data analysis was done on 245 specimens (see figure 1).
Frequency as well as 2 by 2 tables and kappa agreements
were generated in SPSS 11.0 for windows. Sensitivity, specificity
and confidence intervals were analyzed with the meta-disc
software.
Results
Detailed DST results of the LJPM, NRA, MODS and
Genotype MTBDRplus are shown in Table S1.
Interpretable susceptibility results
Using the GenotypeH MTBDRplus assay (Hain Lifescience
GmbH, Germany), 229 (93%) of the 245 studied specimens
showed a clear MTB band on the strip, confirming them as
members of the MTB complex. With the direct NRA, 217 (95%)
of the 229 results were interpretable - 86% at initial testing.
Repeat NRA testing was due to contamination, indeterminate
results or lack of growth in 18(8%), 9(4%) and 4(2%) samples,
respectively. With the direct MODS assay, 217 (95%) of the 229
results were interpretable - 91% at initial testing. Repeat MODS
testing was due to lack of growth in the growth control well
11(5%), contamination 7(3%), and drying in wells 2(1%). Lack of
sufficient growth and contamination accounted for the totally un-
interpretable results (5% of all samples) with both tests (see
Table 1).
Sensitivity and specificity of the direct susceptibility
testing
Of the 217 specimens with interpretable direct NRA or MODS
results, 210 and 207 were interpretable with the LJPM,
respectively, and were used in the analysis for sensitivity and
specificity. Sensitivity was defined as the proportion of drug
resistant strains correctly identified by the study tests (true
positive), and specificity as the proportion of susceptible strains
correctly identified (true negative).
Direct NRA
Sensitivity, specificity and kappa agreement for detection of
MDR were, 97%, 98% and 0.93, respectively. The GenotypeH
MTBDRplus agreed with the NRA for the lone sample regarded as
non-MDR with the NRA but as MDR with the LJPM. If this
sample was regarded as truly non-MDR, the sensitivity of NRA
would potentially increase to 100%. For the three specimens
classified as MDR with the NRA but non-MDR with the LJPM,
the GenotypeH MTBDRplus agreed with the LJPM, but two of
these three specimens were mono-resistant to isoniazid with all
three tests.
Direct MODS
Sensitivity, specificity and kappa agreement for MDR-TB
detection was 87%, 95% and 0.78, respectively. Of the five
specimens categorized as non-MDR with the MODS but MDR
with the LJPM, the GenotypeH MTBDRplus test agreed with the
MODS in only two cases. If these two specimens were to be
included among the true MDR strains, sensitivity of MODS would
potentially increase to 92%. Of the nine specimens categorized as
MDR with MODS but non-MDR with LJPM, the GenotypeH
MTBDRplus test agreed with MODS in only one case; eight
specimens remained non-MDR by the GenotypeH MTBDRplus
test and they were all susceptible to rifampicin in agreement with
the LJPM.
Time to results
Time to results was computed for specimens with interpretable
DST results of both the study test and the GenotypeH MTBDRplus
i.e. 217 specimens for either NRA or MODS. The median time
was 7 days (range 5–38 days) for MODS, 10 days for NRA (range
10–23 days) and 64 days (range 39–215 days) for LJPM. With
MODS, 62% of the results were available by day 7 but by the 14th
day, both MODS and NRA assays had 92% of the results
available (see Table 2).
Cost estimates
The estimated cost of direct susceptibility testing with the NRA
and MODS was $3.58 and $5.56, respectively (see Table 3).
Discussion
The number of TB cases arising annually in Sub Saharan
Africa is alarming (.300 cases per 100, 000 population per
year) [1]. The National TB control programs are however
unable to routinely screen or do surveillance for MDR-TB
due to lack of affordable rapid tests. The overall aim of this
study was to compare two low cost direct DST assays, the
NRA and MODS. We analyzed the proportion of interpretable
results obtained at initial testing, sensitivity, specificity, time to
results, contamination rates, and cost per sample. Interpretable
results were seen in over 90% of the samples with either assays,
most of them at initial testing. Moreover, results in this study
show higher proportion of interpretable results than the
previous reported 80–83% of samples with direct NRA [25–
27] and 89% with MODS [13]. One reason for this could be
that we repeated the tests for all initially un-interpretable results,
unlike previous authors who did not. However, even in our
study, interpretable results obtained at initial testing with
NRA, MODS and LJPM were 186/217 (86%), 197/217
Table 1. Interpretable and Un-interpretable susceptibility
results, (n=229).
Results
Direct NRA
No. (%)
Direct MODS
No. (%)
Indirect LJPM
No. (%)
Interpretable results:
Susceptible to both RIF & INH 149 (65) 143(62) 151 (66)
MDR 39 (17) 44(19) 39 (17)
INH Mono-resistant 24(11) 24(11) 22 (9)
RIF Mono-resistant 5 (2) 6(3) 4 (2)
Subtotal 217 (95) 217 (95) 216(94)
Un-interpretable results:
Insufficient growth 8 (3) 10(4) 6 (3)
Contaminated culture or DST
tube/well
4 (2) 2(1) 7 (3)
Subtotal 12 (5) 12(5) 13 (6)
Total 229 (100) 229 (100) 229 (100)
INH=Isoniazid; LJ PM=Lowenstein-Jensen proportion method;
MDR=Multidrug resistant; MODS=Microscopic Observation Drug
Susceptibility; NRA=Nitrate Reductase Assay; RIF=Rifampicin.
doi:10.1371/journal.pone.0019565.t001
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findings suggest that these assays can be easy to perform in
RLS. The rapid detection of drug resistant TB with the direct
assays would allow a timely decision on therapy. For the few
samples, without interpretable results at initial testing, the main
reason was contamination for direct NRA and lack of growth for
MODS. In the MODS assay, PANTA is included in the
medium, which is not the case for NRA, explaining the
difference in contamination rates. Contrary to the much feared
problem of contamination with direct DST, insufficient growth,
not contamination was the main reason for total failure to
obtain results (Table 1).
Direct Nitrate Reductase Assay
Sensitivity, specificity and kappa agreement for detection of
resistance to RIF, INH and their combination (MDR-TB) was
excellent (Table 4). These findings are in agreement with earlier
reports [11,28] implying that the direct NRA for rapid detection
of MDR-TB can be consistently good across several study
settings. Moreover, for the lone specimen classified as non-MDR
with the NRA but MDR with the LJPM, the GenotypeH
MTBDRplus test agreed with the NRA results, potentially
increasing the sensitivity of direct NRA to 100%. For the three
specimens classified as non-MDR with the LJPM but MDR with
the NRA, the GenotypeH MTBDRplus agreed with the LJPM,
but two of these three specimens were resistant to isoniazid with
all three tests. The excellent sensitivity, specificity, and ease of
implementation show direct NRA to be technically suitable for
rapid diagnosis of MDR-TB in low income high TB burden
countries. Since most of the retreatment patients have non-
MDR disease, this highly sensitive test should be used to rapidly
detect the MDR cases and to confidently exclude the majority
without MDR disease. Early management of detected MDR
cases would begin as further testing continues on only the MDR
cases to confirm their status, thus optimizing the use of scarce
resources.
MODS assay
This test gave good sensitivity and specificity for detection of
resistance to RIF, INH and MDR-TB but the overall
performance was somewhat lower than for NRA, with kappa
agreement for MDR-TB of 0.78 (Table 5). These MODS results
are somewhat less good compared to earlier reports, where
sensitivity and specificity ranged from 92%–100% [11].
Additionally, more cases of false MDR-TB were detected with
the MODS assay compared to the NRA. In our experience
MODS false resistant results could happen if artifacts are
interpreted as cords since the only identification test used was
visual ‘‘cord formation’’. It appears that failure to distinguish
artifacts from cords and non-TB Mycobacterial growth from
MTB cords can lead to a false resistant interpretation. Earlier
reports also found false positive results with the MODS assay
[29]. Recent modification of MODS assay such as addition of a
well with a Para-Nitrobenzoic Acid (PNB) – a reagent that
prevents growth of MTB complex but not other mycobacteria
would help to minimize false resistant results [30]. The MODS
assay is however, potentially an economical test in laboratories
with many samples but less incubator space since one plate is
adequate for at least 4 samples. However, its lower technical
performance compared with NRA in the study setting is a
disadvantage.
Time to results
As expected, both direct tests were far more rapid than
indirect LJPM but with MODS having the shorter median time
to results, i.e. 7 days, but 10 with NRA. Additionally, the
proportion of results obtained within 10 days was slightly
higher for MODS (83%) than for NRA (74%). However, by day
14 both tests had an equal proportion of interpretable results
(92%).
Previous direct NRA studies reported fewer proportions of
results within 10 days compared to our study findings [14–16,25–
27,29]. In those studies, the control tubes received a 1:10 diluted
inoculum while in our study, the same undiluted inoculum was
used in both the controls and drug tubes. Differences among
studies could also be due to different positivity level of AFB in the
sputums since patients in RLS tend to report with advanced
disease. Nevertheless, majority of earlier studies also reported time
to results varying from 10–15 days for around 80% of the samples.
Given the high sensitivity and specificity of direct NRA, a median
time of 10 days appears reasonable for an accurate MDR
diagnosis in a RLS. Moreover, 92% of interpretable results were
obtained within 14 days with NRA as it was for MODS (see
Table 5).
According to the WHO, validated methods that detect
resistance within 2–3 weeks can be recommended for rapid
testing when molecular methods are not available [20]. Thus,
our results comply with the WHO’s recommendation of rapid
DST of M. tuberculosis in settings where molecular tests are
Table 2. DST results obtained within specified days.
Results within
MODS
No. (Cumulative %)
NRA
No. (Cumulative %)
7 days 135 (62) -
10 days 45 (83) 160 (74)
14 days 19 (92) 40 (92)
After 14days 18 (100) 17 (100)
Total 217 (100) 217 (100)
MODS=Microscopic Observation Drug Susceptibility; NRA=Nitrate Reductase
Assay; RIF=Rifampicin.
doi:10.1371/journal.pone.0019565.t002
Table 3. Cost estimation of tests.
Laboratory activity Cost, USD
Direct NRA Direct MODS Indirect LJPM
Sputum processing 2.15 2.15 2.15
Culture before DST NA NA 0.47
Inoculation of Direct
DST
0.53 2.69 NA
Inoculation of indirect
DST
NA NA 0.96
Reading Direct DST 0.43 NA NA
Subtotal 3.11 4.84 3.58
Shipping etc.(15%
of direct costs)
0.47 0.73 0.54
Total cost 3.58 5.56 4.12
DST=Drug susceptibility testing; LJ PM=proportion method on Lowenstein-
Jensen Medium; MODS=Microscopic Observation Drug Susceptibility; NA=Not
Applicable; NRA=Nitrate Reductase Assay; USD=United States dollar.
doi:10.1371/journal.pone.0019565.t003
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setting would represent a significant improvement in MDR
diagnosis from the public health and individual patient
perspectives compared with the indirect LJPM, which in our
study had a median TTR of 64 days.
Cost per sample
The direct consumables cost for sputum processing, inocula-
tion and reading of the susceptibility test were estimated. All three
tests required the same sputum processing cost of $2.15. The
NRA uses almost the same consumables as the LJPM except for
the addition of potassium nitrate in the medium and later
addition of the Griess reagent. However, both direct tests exclude
the need for prior culture to isolate M. tuberculosis before
performing DST, which explains the lower cost of direct NRA
compared to the indirect LJPM (estimated costs $4.12 per
sample). In our setting the direct NRA was cheapest ($3.58 per
sample). The MODS assay requires culture plates, growth
supplements and PANTA that may inevitably increase the cost
per test ($5.56). The MODS assay also requires the use of an
inverted microscope, which is not available in most TB
laboratories in RLS. More recently, a less costly inverted
microscope has been designed and in the future the MODS
assay might cut the investments costs [31]. The differences in
reported costs in our and earlier studies [13] clearly illustrate the
difficulty involved in cost comparison in different settings.
Bio safety
A validated and well maintained class II BSC is needed for the
NRA test. The use of a BSC minimizes significantly the risk of
aerosol inhalation of harmful aerosols.
For the MODS assay since the test is based on liquid media it is
even more important to perform all the procedures from sample
preparation, plate inoculation and plate sealing in a class II BSC.
Extra care should be taken during plate sealing to avoid spillage
and cross contamination between wells. In our experience,
parafilm cracked during incubation and should not be used.
WHO recommends that direct DST, with NRA or MODS can
be carried out in a laboratory with restricted access and a class II
BSC as minimum requirements which is supported by others
[17,32]. Most TB laboratories in RLSs are very basic often the
only bio safety equipment is a class II BSC. In a well managed
laboratory, with appropriate bio safety routines an acceptable bio
safety level can be achieved and the direct DST can be
implemented.
Conclusion
The direct NRA and MODS gave interpretable DST results in
over 90% of smear positive sputum samples mostly within 14 days.
In the study settings, the direct NRA was highly sensitive, specific
and somewhat cheaper. We consider the direct NRA to have a
strong potential for the direct detection of MDR-TB in resource-
limited settings.
Table 5. Technical performance of the direct MODS assay (n=207).
MODS LJPM
Sensitivity
%
Specificity
% Kappa Agreement
PPV
%
NPV
%
RS
RIF R 36 11 88 (95% CI 73–96) 93 (95% CI 88–97) 0.77 75 97
S 5 155
INH R 53 11 90 (95% CI 79–96) 93 (95% CI 87–96) 0.80 83 96
S 6 137
RIF+INH
(MDR)
R 32 9 87 (95% CI 71–96) 95 (95% CI 90–98) 0.78 78 97
S 5 161
S=susceptible; R=resistant; LJPM=proportion method on Lowenstein-Jensen Medium; MDR=multidrug resistant; NPV=negative predictive value; PPV=positive
predictive value; MODS=Microscopic Observation Drug Susceptibility; RIF=rifampicin; INH=isoniazid.
doi:10.1371/journal.pone.0019565.t005
Table 4. Technical performance of the direct NRA (n=210).
NRA LJPM
Sensitivity
%
Specificity
% Kappa Agreement
PPV
%
NPV
%
RS
RIF R 40 4 98 (95% CI 87–100) 98 (95% CI 94–99) 0.93 91 99
S 1 165
INH R 56 6 93 (95% CI 83–98) 96 (95% CI 91–99) 0.88 90 97
S 4 144
RIF+INH
(MDR)
R 36 3 97 (95% CI 85–100) 98 (95% CI 95–100) 0.93 92 99
S 1 170
INH=Isoniazid; LJPM=Lowenstein-Jensen proportion method; MDR=multidrug resistant; NPV=Negative predictive value; NRA=Nitrate Reductase Assay;
PPV=positive predictive value; R=resistant; RIF=Rifampicin; S=susceptible.
doi:10.1371/journal.pone.0019565.t004
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